Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Authors' conclusion
Our results support a possible role of subcutaneous tocilizumab in anti-TNF refractory uveitis.
Study context
- Population
- Children with anti-TNF refractory non-infectious uveitis
- Participants
- 5 children
- Outcome
- Serum tocilizumab concentration and clinical response
Methodological detailsbrief report
- Brief report
Main finding
As reported in the abstract
Serum tocilizumab concentration (ELISA)
- Higher values than levels recorded in adult patients with RA treated with intravenous tocilizumab
Observational data: associations, not effects.
Further findings
Clinical response (slit lamp)
- Clinical remission
- 3
- Mild relapse, treated with topical steroids
- 1
- No response
- 1
Safety
Tolerability
- Well tolerated without severe infection or other adverse events
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report. Pediatr Rheumatol Online J. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →